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Background
Designed Ankyrin Repeat proteins (DARPins) are a novel
type of binding protein scaffold designed as antibody alter-
native for biomedical applications. DARPins share many
properties with antibodies, most noteworthy a high target
specificity and affinity, but they differ from antibodies in
size, structure and binding pattern and, importantly, favor-
able biophysical properties such as exceptional stability.
This together with high-yield prokaryotic production ren-
ders DARPins promising candidates for microbicide
development.
Methods
DARPin DNA libraries encoding either two or three inter-
nal ankyrin repeats were subjected to ribosome display
selections and panned against recombinant gp120 pro-
teins. Wild type, CD4 induced, V1V2 truncated and degly-
cosylated JR-FL gp120, as well as structural V3 loop
mimetics were probed as target. Obtained DARPin clones
were sequenced, mapped for reactivity with HIV gp120 by
ELISA and probed for inhibitory activity using the TZM-
bl pseudotype virus inhibition assay.
Results
DARPin selection proved more successful when confor-
mationally arrested targets were used for panning. Overall,
gp120-specific DARPins recognizing a variety of epitopes
including the CD4bs, CD4i and the V3 loop were
obtained. Gp120 mutant binding analysis revealed that
DARPin molecules depended to a higher degree on a
structural conservation of the envelope protein than gp120
specific antibodies recognizing overlapping domains. Most
noteworthy, V3 loop specific clones were selected, which
unlike V3 loop antibodies, recognized the V3 loop in a
conformation-dependent manner and thus do not effi-
ciently bind linear V3 loop peptides. In contrast to V3-
loop directed antibodies these DARPins proved to bypass
the envelope shielding by the V1V2 domain and thus were
capable of neutralizing TIER-2 viruses.
Conclusion
Gp120 proved a challenging target for selection of DAR-
Pin binders against gp120. Nonetheless, by combining
different selection strategies we were able to derive a
variety of gp120-specific DARPin molecules, including
some with unique HIV entry blocking activity.
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